Evista Approval For Breast Cancer Risk Reduction Comes With “Black Box” On VTE, Stroke
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly’s osteoporosis drug is cleared for use in reducing the risk of invasive breast cancer in two female patient populations.